Krystal Biotech Stock Filter Stocks by Fundamentals
| KRYS Stock | USD 156.07 0.23 0.15% |
Krystal Biotech fundamentals help investors to digest information that contributes to Krystal Biotech's financial success or failures. It also enables traders to predict the movement of Krystal Stock. The fundamental analysis module provides a way to measure Krystal Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Krystal Biotech stock.
Krystal | Shares Owned by Institutions |
Krystal Biotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Krystal Biotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Krystal Biotech's managers, analysts, and investors.Environmental | Governance | Social |
Krystal Biotech Institutional Holders
Institutional Holdings refers to the ownership stake in Krystal Biotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Krystal Biotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Krystal Biotech's value.| Shares | Jennison Associates Llc | 2024-09-30 | 410.1 K | Amvescap Plc. | 2024-09-30 | 365.6 K | Nuveen Asset Management, Llc | 2024-09-30 | 311.9 K | Goldman Sachs Group Inc | 2024-09-30 | 301.4 K | Lord, Abbett & Co Llc | 2024-09-30 | 284.2 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 275.8 K | Franklin Resources Inc | 2024-09-30 | 243.8 K | Charles Schwab Investment Management Inc | 2024-09-30 | 240.2 K | Northern Trust Corp | 2024-09-30 | 238.7 K | Fmr Inc | 2024-09-30 | 4.3 M | Blackrock Inc | 2024-09-30 | 4 M |
Krystal Fundamentals
| Return On Equity | 0.0638 | ||||
| Return On Asset | 0.0458 | ||||
| Profit Margin | 0.22 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 3.91 B | ||||
| Shares Outstanding | 28.76 M | ||||
| Shares Owned By Insiders | 12.12 % | ||||
| Shares Owned By Institutions | 87.88 % | ||||
| Number Of Shares Shorted | 3.25 M | ||||
| Price To Earning | (6.36) X | ||||
| Price To Book | 5.07 X | ||||
| Price To Sales | 18.61 X | ||||
| Revenue | 50.7 M | ||||
| Gross Profit | 223.54 M | ||||
| EBITDA | 17.9 M | ||||
| Net Income | 10.93 M | ||||
| Cash And Equivalents | 425.56 M | ||||
| Cash Per Share | 16.58 X | ||||
| Total Debt | 8.09 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 12.45 X | ||||
| Book Value Per Share | 30.80 X | ||||
| Cash Flow From Operations | (88.8 M) | ||||
| Short Ratio | 10.79 X | ||||
| Earnings Per Share | 1.78 X | ||||
| Target Price | 206.25 | ||||
| Number Of Employees | 229 | ||||
| Beta | 0.82 | ||||
| Market Capitalization | 4.5 B | ||||
| Total Asset | 818.36 M | ||||
| Retained Earnings | (269.83 M) | ||||
| Working Capital | 554.82 M | ||||
| Current Asset | 2.05 M | ||||
| Current Liabilities | 40.74 K | ||||
| Net Asset | 818.36 M |
About Krystal Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Krystal Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Krystal Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Krystal Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Krystal Stock Analysis
When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.